UBS Group
ZYNE

UBS Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

UBS Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-31,000
Closed -$420K – 8357
2019
Q2 		$420K Buy
+31,000
New +$358K ﹤0.01% 4417

UBS Group's ZYNE Position: Q4 2023 in Review

UBS Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 20,385 shares — an estimated $26K sold.

UBS Group first reported a position in ZYNE in Q3 2015 and held it in 31 quarters. The position peaked at $635K in Q2 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

  • UBS Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 20,385 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $26K.
  • UBS Group first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 31 quarters.
  • UBS Group's Zynerba Pharmaceuticals, Inc position peaked at $635K in Q2 2019.
  • 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.